Cardiol Therapeutics (CRDL) Competitors

ProKidney (NASDAQ:PROK) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.

Is PROK or CRDL more profitable?

ProKidney's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-10.24%
Cardiol Therapeutics	N/A	-118.65%	-85.28%

Which has more volatility and risk, PROK or CRDL?

ProKidney has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of PROK or CRDL?

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 41.5% of ProKidney shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media refer more to PROK or CRDL?

In the previous week, ProKidney had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for ProKidney and 3 mentions for Cardiol Therapeutics. ProKidney's average media sentiment score of 0.87 beat Cardiol Therapeutics' score of 0.43 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer PROK or CRDL?

ProKidney presently has a consensus target price of $4.50, suggesting a potential upside of 165.49%. Cardiol Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 380.77%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Which has preferable valuation and earnings, PROK or CRDL?

Cardiol Therapeutics has higher revenue and earnings than ProKidney. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	N/A	N/A	-$35.47M	-$0.55	-3.08
Cardiol Therapeutics	$60K	2,423.63	-$20.84M	-$0.39	-4.67

Does the MarketBeat Community favor PROK or CRDL?

Cardiol Therapeutics received 14 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 61.11% of users gave Cardiol Therapeutics an outperform vote while only 57.14% of users gave ProKidney an outperform vote.

Company	Underperform	Outperform
ProKidney	Outperform Votes 8 57.14%	Underperform Votes 6 42.86%
Cardiol Therapeutics	Outperform Votes 22 61.11%	Underperform Votes 14 38.89%

Summary

Cardiol Therapeutics beats ProKidney on 9 of the 17 factors compared between the two stocks.